Notably, upregulation of ERAP1 and ERAP2 in ERAP-low tumor cells was found to enhance HLA class I surface expression, suggesting that abnormal HLA class I levels in tumor cells may result from defective expression of these enzymes (39). This evidence concerns the gene ERAP2 and neoplasm.